2Anno
I think the investment horizon is too short for the company... the potential price movers will only come towards fall
••
@MaxD Quite possibly, but I don't think it's so wrong to bet on a rebound in biotech at the moment. Like China Tech, XBI peaked in February 21 and has imploded epochally since then. I think the bottom will also be found there before it is the case in the Nasdaq / SPY. IBRX is already a good 50% up from the bottom.
•
11
•2Anno
@ClermitInvest I am fundamentally with you and generally very bullish for the IBRX path. The rebound can of course come and IBRX is certainly in the biotech rebound due to its relaxed financial situation and (hopefully) final stage of unprofitability. But well... let's see, I still think it will take until the fall
•
22
•